CONTACT
+91 80 2808 2808
info@biocon.com

Biocon’s APIs Manufacturing Facility in Telangana Completes U.S. FDA Inspection with No 483 Observations

  • Posted by: BIOCON

Bengaluru, India, December 17, 2018

“The U.S. FDA conducted a GMP inspection of our APIs manufacturing facility at Telangana from Dec 12- Dec 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects our strong commitment to quality and cGMP compliance.”

– Company Spokesperson

Author: BIOCON
Share
Previous Next
Close
Test Caption
Test Description goes like this